資產可視化：全球製藥行業的卡車和追蹤法規

本報告探討資產可視化，重點關注全球製藥行業的跟蹤和追溯監管，並提供有關全球和區域監管環境、合規性、實施規模和範圍、關鍵公司等方面的信息。

調查重點

• 關注新興市場（巴西、南非、阿拉伯聯合酋長國、沙特阿拉伯、土耳其）
• 識別區域和國家監管趨勢之間的差異
• 各層級序列化對比分析

本報告回答的主要問題

• 連載規則介紹時間表
• 可追溯性的關鍵數據標準和義務是什麼？
• 在國家法規中如何使用 GS1 等國際標準？

本報告所列公司

目錄

• 執行摘要
• 全球監管環境
• 區域監管環境
• 主要用途
• 國內法規和國際標準
• 提案系統概述
• 合規：義務和自願的最佳做法
• 報告要求
• 負責卡車和追蹤的供應商/第三方
• 出色的分發工作
• 罰款和罰款
• 實施規模和範圍
• 需要追蹤的物品
• 建議的未來修復
• 結論
• 定義和縮寫

Actionable Benefits:

• Strategic planning for pharmaceutical vendors and distributors for changes in serialization regulations.

• Gain insight into scale and scope of current regulations.

• Guidance into proposed future regulatory changes.

Research Highlights:

• Focus on emerging markets (Brazil, South Africa, UAE, Saudi Arabia, and Turkey)

• Identifies variation between region-level trends and country-level regulations.

• Comparison and analysis of different levels of serialization.

Critical Questions Answered:

• What is the timeline for implementation of serialization regulations?

• What are the key data standards and mandates for traceability?

• How are international standards like GS1 leveraged in national regulations?

Who Should Read This?

• Strategy planners and advisors within the pharmaceutical and supporting logistics industry.

• Managers aiming to identify regulatory requirements of their operations.

• For serialization software and hardware providers to assess regulatory impact on the pharmaceutical market.

Companies Mentioned:

Table of Contents

• Executive Summary
• Global Regulatory Environment
• Regional Regulatory Environment
• Key Objectives
• National Regulations and International Standards
• Summary of Proposed System
• Compliance: Mandates versus Voluntary Best Practices
• Reporting Requirements
• Suppliers and Third Parties Responsible for Track & Trace
• Good Distribution Practices
• Penalties and Fines
• Scale and Scope of Implementations
• Items Subject to Track & Trace
• Future Amendments Proposed
• Conclusion
• Definitions and Abbreviations